Cardiff Oncology (Seite 3)
eröffnet am 22.09.20 01:19:21 von
neuester Beitrag 09.04.24 07:30:48 von
neuester Beitrag 09.04.24 07:30:48 von
Beiträge: 109
ID: 1.331.278
ID: 1.331.278
Aufrufe heute: 0
Gesamt: 8.299
Gesamt: 8.299
Aktive User: 0
ISIN: US14147L1089 · WKN: A2P4GU · Symbol: CRDF
4,0700
USD
+2,01 %
+0,0800 USD
Letzter Kurs 02:00:00 Nasdaq
Neuigkeiten
25.04.24 · globenewswire  |
08.04.24 · globenewswire |
06.03.24 · globenewswire |
01.03.24 · wO Chartvergleich |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 0,5922 | +44,44 | |
| 7,3500 | +43,84 | |
| 11,690 | +40,84 | |
| 0,7000 | +36,69 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,110 | -13,44 | |
| 8,2200 | -13,47 | |
| 7,6100 | -17,20 | |
| 1,6100 | -18,27 | |
| 2,1200 | -21,77 |
Beitrag zu dieser Diskussion schreiben
Feedback
https://www.stocktitan.net/news/CRDF/cardiff-oncology-report…
Upcoming expected milestones
mPDAC data readout from Phase 2 trial expected in Q3 '23
SCLC data readout from Phase 2 trial expected in Q3 '23 (investigator-initiated trial with UPMC)
First patient dosed in first-line mCRC trial expected fall '23
TNBC data readout from Phase 1b/2 trial expected Q4 '23/Q1 '24 (investigator-initiated trial with Dana-Farber Cancer Institute)
First-line mCRC randomized data readout expected in mid-2024
Upcoming expected milestones
mPDAC data readout from Phase 2 trial expected in Q3 '23
SCLC data readout from Phase 2 trial expected in Q3 '23 (investigator-initiated trial with UPMC)
First patient dosed in first-line mCRC trial expected fall '23
TNBC data readout from Phase 1b/2 trial expected Q4 '23/Q1 '24 (investigator-initiated trial with Dana-Farber Cancer Institute)
First-line mCRC randomized data readout expected in mid-2024
Antwort auf Beitrag Nr.: 74.277.171 von Univego am 08.08.23 08:17:00Ja. Klasse News !
Gab nachbörslich tolle News von Cardiff. Der Kurs zog dann gleich mal über 20% an. Zur Erinnerung: Cardiffs Marketcap liegt auch nach dem Anstieg unter dem Cashbestand !! Ca. 70Mio$ gg. 89Mio$. Ein absoluter Witz. Durch Pfizer wird es keine Geldsorgen geben, Pfizer wird m.E. irgendwann vor Veröffentlichung der Studiendaten ein BO Angebot unterbreiten. Onvantersib hat alles für eine neue SOC (standard of care) Behandlung, und damit wäre es ein Blockbustermedikament. https://finance.yahoo.com/news/cardiff-oncology-announces-le…
Da sind wir mal heute Nachmittag gespannt, was die Amis draus machen. Kann alles passieren, sowohl nach oben als auch nach unten, aber eigentlich (!) kann es die nächste Zeit nur nach oben gehen. Cardiff könnte seine eigenen Aktien (theoretisch!) mit ihren Barmitteln komplett kaufen und hätte immer noch fast 20 Mio$ in der Kasse. Das ist einfach nur schräg und unglaublich.
Aaaber in der heutigen Zeit hat man schon viele Pferde kotzen gesehen, es ist alles kurzsichtiger geworden, leider!
(In eigener Sache: Hab ja seit einigen Monaten wenig Zeit aufgrund von aufwändigen Renovierungsarbeiten meines Elternhauses, aber dafür mußte ich mich dann doch hier wieder mal einloggen)
Gab nachbörslich tolle News von Cardiff. Der Kurs zog dann gleich mal über 20% an. Zur Erinnerung: Cardiffs Marketcap liegt auch nach dem Anstieg unter dem Cashbestand !! Ca. 70Mio$ gg. 89Mio$. Ein absoluter Witz. Durch Pfizer wird es keine Geldsorgen geben, Pfizer wird m.E. irgendwann vor Veröffentlichung der Studiendaten ein BO Angebot unterbreiten. Onvantersib hat alles für eine neue SOC (standard of care) Behandlung, und damit wäre es ein Blockbustermedikament. https://finance.yahoo.com/news/cardiff-oncology-announces-le…
Da sind wir mal heute Nachmittag gespannt, was die Amis draus machen. Kann alles passieren, sowohl nach oben als auch nach unten, aber eigentlich (!) kann es die nächste Zeit nur nach oben gehen. Cardiff könnte seine eigenen Aktien (theoretisch!) mit ihren Barmitteln komplett kaufen und hätte immer noch fast 20 Mio$ in der Kasse. Das ist einfach nur schräg und unglaublich.
Aaaber in der heutigen Zeit hat man schon viele Pferde kotzen gesehen, es ist alles kurzsichtiger geworden, leider!
(In eigener Sache: Hab ja seit einigen Monaten wenig Zeit aufgrund von aufwändigen Renovierungsarbeiten meines Elternhauses, aber dafür mußte ich mich dann doch hier wieder mal einloggen)
Ja, wer hätte das gedacht… Pfizer ist mit im Boot und sehr gute Ergebnisse!!! Bin gespannt auf heute Nachmittag…
https://cardiffoncology.investorroom.com/2023-08-07-Cardiff-…
https://cardiffoncology.investorroom.com/2023-08-07-Cardiff-…
Das kann morgen ein sehr interessanter Tag werden 🥂💕🥂...
Trading Spotlight
Congratulations to UPMC, Taofeek Owonikoko, MD, PhD and John Schmitz on the great poster presentation on the investigator initiated research using Cardiff Oncology’s onvansertib, "Targeting PLK1 effectively suppresses growth of small cell lung cancer.”
Our Director of Research and Development Maya Ridinger, PhD was excited to attend the American Association for Cancer Research annual meeting and see the poster firsthand.
Learn more: https://lnkd.in/e362SJUH #AACR23 #lungcancer
https://www.linkedin.com/posts/cardiffoncology_aacr23-lungca…
Our Director of Research and Development Maya Ridinger, PhD was excited to attend the American Association for Cancer Research annual meeting and see the poster firsthand.
Learn more: https://lnkd.in/e362SJUH #AACR23 #lungcancer
https://www.linkedin.com/posts/cardiffoncology_aacr23-lungca…
https://www.technologynetworks.com/drug-discovery/product-ne…
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, has announced that the first patient was dosed last month with its investigational drug onvansertib in its Phase 2 ONSEMBLE trial (NCT05593328). The trial is designed to demonstrate a clinically meaningful difference in response and onvansertib's contribution to standard of care (SoC) FOLFIRI/bevacizumab for the second line treatment of patients with KRAS/NRAS-mutated metastatic colorectal cancer (mCRC).
"We are excited to be underway with our ONSEMBLE trial that builds on the promising efficacy and tolerability results demonstrated in our phase 1b/2 trial in mCRC," said Fairooz Kabbinavar, MD, Chief Medical Officer of Cardiff Oncology. "mCRC is a difficult-to-treat cancer and patients in the second line setting need novel therapeutic options to improve clinical outcomes. Based on our open-label phase 1b/2 trial, we believe the combination of onvansertib with FOLFIRI/bevacizumab could positively impact patients' responses to treatment and the durability of the responses. Nearly half of our planned 40 sites in the US are open to enroll patients and we've seen great enthusiasm from participating investigators."
The Phase 2 ONSEMBLE trial includes patients with mCRC who have a documented KRAS or NRAS mutation and have previously received one prior chemotherapy regimen with or without bevacizumab in the first line metastatic setting. Patients are being randomized to onvansertib plus FOLFIRI/bevacizumab versus FOLFIRI/bevacizumab (standard of care). The primary endpoint is objective response rate determined by the Response Evaluation Criteria in Solid Tumors via an independent central review. The secondary endpoints include progression-free survival, overall survival, duration of response and safety. The trial is being led by Heinz-Josef Lenz, MD, USC Norris Comprehensive Cancer Center, who has experience with the Company's mCRC clinical program, having served as the principal investigator for the Phase 1b/2 trial.
The Company recently introduced the members of its Scientific Advisory Board, which will continue to provide insight and guidance related to the ONSEMBLE trial and its strategy to advance onvansertib through later-stage clinical development.
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, has announced that the first patient was dosed last month with its investigational drug onvansertib in its Phase 2 ONSEMBLE trial (NCT05593328). The trial is designed to demonstrate a clinically meaningful difference in response and onvansertib's contribution to standard of care (SoC) FOLFIRI/bevacizumab for the second line treatment of patients with KRAS/NRAS-mutated metastatic colorectal cancer (mCRC).
"We are excited to be underway with our ONSEMBLE trial that builds on the promising efficacy and tolerability results demonstrated in our phase 1b/2 trial in mCRC," said Fairooz Kabbinavar, MD, Chief Medical Officer of Cardiff Oncology. "mCRC is a difficult-to-treat cancer and patients in the second line setting need novel therapeutic options to improve clinical outcomes. Based on our open-label phase 1b/2 trial, we believe the combination of onvansertib with FOLFIRI/bevacizumab could positively impact patients' responses to treatment and the durability of the responses. Nearly half of our planned 40 sites in the US are open to enroll patients and we've seen great enthusiasm from participating investigators."
The Phase 2 ONSEMBLE trial includes patients with mCRC who have a documented KRAS or NRAS mutation and have previously received one prior chemotherapy regimen with or without bevacizumab in the first line metastatic setting. Patients are being randomized to onvansertib plus FOLFIRI/bevacizumab versus FOLFIRI/bevacizumab (standard of care). The primary endpoint is objective response rate determined by the Response Evaluation Criteria in Solid Tumors via an independent central review. The secondary endpoints include progression-free survival, overall survival, duration of response and safety. The trial is being led by Heinz-Josef Lenz, MD, USC Norris Comprehensive Cancer Center, who has experience with the Company's mCRC clinical program, having served as the principal investigator for the Phase 1b/2 trial.
The Company recently introduced the members of its Scientific Advisory Board, which will continue to provide insight and guidance related to the ONSEMBLE trial and its strategy to advance onvansertib through later-stage clinical development.
Durchsuchen
Cardiff Oncology
